Form 4: Keros Therapeutics Director and 10% Owner Reports Significant Equity Awards

Ran Nussbaum, a Director and 10% Owner of Keros Therapeutics, Inc., reported the acquisition of 5,250 restricted stock units and 10,500 stock options on June 4, 2025.

Summary

• Ran Nussbaum, a Director and 10% Owner of Keros Therapeutics, Inc. (KROS), reported new equity awards on June 4, 2025.
• The awards include 5,250 Restricted Stock Units (RSUs) granted at a price of $0, which will fully vest on the earlier of June 4, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• Additionally, Mr. Nussbaum was granted 10,500 stock options with an exercise price of $14.82 per share, which will vest in equal quarterly installments over 12 months, fully vesting by the Issuer's 2026 annual meeting, subject to continued service.
• Following these transactions, Mr. Nussbaum directly beneficially owns 5,250 shares of Common Stock (RSUs) and 10,500 stock options.
• Indirectly, Mr. Nussbaum is deemed to share voting and investment power over 2,284,612 shares held by Israel IV, 1,121,045 shares held by Cayman IV, and 1,226,412 shares held by China IV, through his role as a Managing Partner of Pontifax Management 4 G.P. (2015) Ltd., the ultimate general partner of these entities. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The filing indicates standard equity compensation for a director and 10% owner, aligning their interests with the company's performance, which is generally positive for corporate governance and long-term strategy. It does not contain negative news or unexpected events.

Positives

• The equity awards (RSUs and stock options) align the interests of a key director and 10% owner with the long-term performance of Keros Therapeutics, Inc.
• The grants are a standard form of compensation, indicating continued commitment and incentivization for the reporting person.

Negatives

• The RSUs and stock options are subject to vesting conditions, primarily continued service, meaning the full benefit is not immediate.
• The value of the stock options is dependent on the future market price of KROS exceeding the exercise price of $14.82.

Risks

• The vesting of both RSUs and stock options is contingent upon the Reporting Person continuing to provide service to the Issuer through the specified vesting dates.
• The value realized from the stock options is subject to market fluctuations; if the stock price does not rise above the exercise price of $14.82, the options may not be profitable.
• The indirect beneficial ownership through investment funds involves disclaimers of full beneficial ownership, limiting the direct control or pecuniary interest of the Reporting Person over those shares.

Future Outlook

The equity awards are designed to incentivize the director for future performance, with vesting schedules extending into 2026, aligning his financial interests with the company's long-term success and shareholder value creation.

Industry Context

The granting of restricted stock units and stock options is a common practice in the biotechnology and pharmaceutical industries for compensating directors and executives, aiming to align their interests with the company's long-term strategic goals and shareholder returns.

Stakeholder Impact

• Shareholders: Increased alignment of a significant insider's interests with long-term company performance due to equity awards, potentially fostering more strategic decision-making aimed at increasing shareholder value.

Next Steps

• Continued service by Ran Nussbaum to meet the vesting conditions for the RSUs and stock options.
• Potential future exercise of stock options by Ran Nussbaum once vested and if the stock price is favorable.

Key Dates

Keywords

Keros Therapeutics, KROS, Ran Nussbaum, Form 4, SEC filing, insider transaction, stock options, restricted stock units, RSU, beneficial ownership, equity compensation, corporate governance